JP2012143232A5 - - Google Patents

Download PDF

Info

Publication number
JP2012143232A5
JP2012143232A5 JP2012021947A JP2012021947A JP2012143232A5 JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5 JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
monoclonal antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012021947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012143232A (ja
JP5420688B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012021947A priority Critical patent/JP5420688B2/ja
Priority claimed from JP2012021947A external-priority patent/JP5420688B2/ja
Publication of JP2012143232A publication Critical patent/JP2012143232A/ja
Publication of JP2012143232A5 publication Critical patent/JP2012143232A5/ja
Application granted granted Critical
Publication of JP5420688B2 publication Critical patent/JP5420688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012021947A 2005-12-20 2012-02-03 抗ilt7抗体 Active JP5420688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
JP2005366465 2005-12-20
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007551124A Division JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Publications (3)

Publication Number Publication Date
JP2012143232A JP2012143232A (ja) 2012-08-02
JP2012143232A5 true JP2012143232A5 (enExample) 2013-04-25
JP5420688B2 JP5420688B2 (ja) 2014-02-19

Family

ID=38188642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体
JP2012021947A Active JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Country Status (29)

Country Link
US (6) US8084585B2 (enExample)
EP (4) EP1964852B1 (enExample)
JP (2) JP5020828B2 (enExample)
KR (3) KR101624587B1 (enExample)
CN (5) CN120718150A (enExample)
AU (1) AU2006328470B2 (enExample)
BR (1) BRPI0620141B1 (enExample)
CA (2) CA2994756C (enExample)
CY (3) CY1114227T1 (enExample)
DK (3) DK2913343T3 (enExample)
ES (3) ES2416716T3 (enExample)
HK (1) HK1218126A1 (enExample)
HR (2) HRP20130494T1 (enExample)
HU (1) HUE039865T2 (enExample)
IL (1) IL192266A (enExample)
LT (1) LT2913343T (enExample)
ME (1) ME02111B (enExample)
MX (1) MX2008007682A (enExample)
NZ (3) NZ599683A (enExample)
PL (3) PL2913343T3 (enExample)
PT (3) PT2532681E (enExample)
RS (2) RS52860B (enExample)
RU (2) RU2456298C2 (enExample)
SG (2) SG10201602095PA (enExample)
SI (3) SI1964852T1 (enExample)
TR (1) TR201816574T4 (enExample)
UA (1) UA97946C2 (enExample)
WO (1) WO2007072866A1 (enExample)
ZA (1) ZA200805850B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
KR20170085143A (ko) 2010-02-24 2017-07-21 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US9096660B2 (en) 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
CA3182262A1 (en) 2011-04-01 2012-10-04 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
RS58910B1 (sr) 2012-03-20 2019-08-30 Biogen Ma Inc Antitela koja neutrališu virus jcv
DK2828292T3 (da) * 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
CN111499755A (zh) * 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
WO2014036495A2 (en) 2012-08-31 2014-03-06 Immunogen Inc. Diagnostic assays and kits for detection of folate receptor 1
RS62240B1 (sr) 2013-08-30 2021-09-30 Immunogen Inc Antitela i testovi za detekciju folatnog receptora 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
PT3218005T (pt) 2014-11-12 2023-04-11 Seagen Inc Compostos que interagem com glicano e métodos de uso
MX382582B (es) * 2015-03-18 2025-03-13 Seagen Inc Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
BR112017027254A2 (pt) * 2015-06-29 2019-05-14 Immunogen, Inc. anticorpos anti-cd123 e conjugados e derivados dos mesmos
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン, インコーポレイテッド 抗folr1免疫複合体を含む治療組み合わせ
JP7066613B2 (ja) 2015-11-12 2022-05-13 シージェン インコーポレイテッド グリカン相互作用化合物および使用方法
CA3005469A1 (en) * 2015-11-19 2017-05-26 Abbvie Stemcentrx Llc Novel anti-emr2 antibodies and methods of use
US20190038367A1 (en) 2016-01-26 2019-02-07 Cyberdontics, Inc. Automated dental treatment system
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
IL296874A (en) 2016-03-01 2022-11-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
BR112018067951A2 (pt) * 2016-03-10 2019-02-05 Viela Bio, Inc. moléculas que se ligam a ilt7 e métodos de uso destas
EA201892225A1 (ru) 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2018323955A1 (en) * 2017-08-30 2020-03-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
JOP20200131A1 (ar) * 2017-11-17 2020-05-28 Merck Sharp & Dohme أجسام مضادة خاصة بنسخة تشبه جلوبيولين مناعي 3 (ilt3) واستخدامتها
CA3086009A1 (en) * 2017-12-20 2019-06-27 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
CA3099429A1 (en) 2018-05-10 2019-11-14 Cyberdontics (Usa), Inc. Automated dental drill
CN114555637A (zh) * 2019-08-12 2022-05-27 比昂生物制剂公司 针对ilt2的抗体及其用途
EP4069288A4 (en) * 2019-12-06 2024-01-17 Viela Bio, Inc. TREATMENT METHODS USING ILT7 BINDING PROTEINS
US11242382B2 (en) 2020-04-20 2022-02-08 Genzyme Corporation Humanized anti-complement factor Bb antibodies
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置
MX2023013015A (es) * 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
TW202404640A (zh) 2022-07-27 2024-02-01 美商維埃拉生物股份有限公司 包含免疫球蛋白樣轉錄本7(ilt7)結合蛋白之調配物
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
AU2024235162A1 (en) * 2023-03-16 2025-09-11 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
CA2494706A1 (en) * 2001-10-13 2003-04-24 Asterion Limited Chimeric glycosylphosphatidylinositol containing peptides
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP2157524A3 (en) 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Similar Documents

Publication Publication Date Title
JP2012143232A5 (enExample)
JP2014526898A5 (enExample)
JP2018536393A5 (enExample)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2017114866A5 (enExample)
JP2020536488A5 (enExample)
JP2013538057A5 (enExample)
JP2012501669A5 (enExample)
JP2014516540A5 (enExample)
JP2014524733A5 (enExample)
JP2011527899A5 (enExample)
JP2014534207A5 (enExample)
JP2012501670A5 (enExample)
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
JP2016026303A5 (enExample)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2020501532A5 (enExample)
CN104086652B (zh) 抗o型口蹄疫病毒特异性单域抗体及其重组表达载体
JP2014518883A5 (enExample)
JP2012012402A5 (enExample)
JP2016516400A5 (enExample)
RU2017107773A (ru) Антитела, специфичные к ммр9
JP2017508475A5 (enExample)
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
JP2014511680A5 (enExample)